Omeprazole: The first proton pump inhibitor

[1]  F. Sundler,et al.  Omeprazole and ranitidine, antisecretagogues with different modes of action, are equally effective in causing hyperplasia of enterochromaffin-like cells in rat stomach , 1989, Regulatory Peptides.

[2]  J. Rask-Madsen,et al.  Effect of 10 mg and 20 mg omeprazole daily on duodenal ulcer: double‐blind comparative trial , 1989, Alimentary pharmacology & therapeutics.

[3]  P. Lindberg,et al.  Chemical Reactions of Omeprazole and Omeprazole Analogues. II. Kinetics of the Reaction of Omeprazole in the Presence of 2-Mercaptoethanol. , 1989 .

[4]  M. Classen,et al.  Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. , 1989, The New England journal of medicine.

[5]  F. Sundler,et al.  Time-course of development and reversal of gastric endocrine cell hyperplasia after inhibition of acid secretion. Studies with omeprazole and ranitidine in intact and antrectomized rats. , 1988, Gastroenterology.

[6]  J. Brunkwall,et al.  The effects of omepmzole and cimetidine on duodenal ulcer healing and ihe relief of symptoms , 1988 .

[7]  D. Graham,et al.  Antacid maintenance therapy in the prevention of duodenal ulcer relapse. , 1988, Gut.

[8]  J. Dent,et al.  Healing and relapse of severe peptic esophagitis after treatment with omeprazole. , 1988, Gastroenterology.

[9]  B. Wallmark,et al.  Specific labelling of gastric H+,K+-ATPase by omeprazole , 1988 .

[10]  L. Lundell,et al.  Omeprazole or ranitidine in the treatment of reflux esophagitis. Results of a double-blind, randomized, Scandinavian multicenter study. , 1988, Scandinavian journal of gastroenterology.

[11]  S. Yu,et al.  Substituted 2-[(2-benzimidazolylsulfinyl)methyl]anilines as potential inhibitors of H+/K+ ATPase. , 1988, Journal of medicinal chemistry.

[12]  R. Hunt,et al.  Omeprazole (20 mg daily) versus cimetidine (1200 mg daily) in duodenal ulcer healing and pain relief. , 1988, Gastroenterology.

[13]  F. Oleson,et al.  Gastric Enterochromaffin-Like Cell Hyperplasia and Neoplasia in the Rat: An Indirect Effect of the Histamine H2-Receptor Antagonist, BL-6341 , 1988, Toxicologic pathology.

[14]  G. Betton,et al.  Gastric ECL-Cell Hyperplasia and Carcinoids in Rodents Following Chronic Administration of H2-Antagonists SK&F 93479 and Oxmetidine and Omeprazole , 1988, Toxicologic pathology.

[15]  J. Crissman,et al.  Morphologic Stomach Findings in Rats and Mice Treated with the H2 Receptor Antagonists, ICI 125,211 and ICI 162,846 , 1988, Toxicologic pathology.

[16]  K. A. Lloyd-Davies,et al.  Omeprazole in the treatment of Zollinger—Ellison syndrome: a 4‐year international study , 1988, Alimentary pharmacology & therapeutics.

[17]  H. Wulff,et al.  Effect of omeprazole and cimetidine on prepyloric gastric ulcer: double blind comparative trial. , 1988, Gut.

[18]  C. Fenger,et al.  Omeprazole and ranitidine in treatment of reflux oesophagitis: double blind comparative trial , 1988, British medical journal.

[19]  J. Senn‐Bilfinger,et al.  (H+-K+)-ATPase inhibiting 2-[(2-pyridylmethyl)sulfinyl]benzimidazoles. 2. The reaction cascade induced by treatment with acids. Formation of 5H-pyrido[1',2':4,5][1,2,4]thiadiazino[2,3-a]benzimidazol-13-ium salts and their reactions with thiols , 1987 .

[20]  P. Lindberg,et al.  Structure—activity relationships of omeprazole analogues and their mechanism of action , 1987 .

[21]  J. Senn‐Bilfinger,et al.  (H+-K+)-ATPase inhibiting 2-[(2-pyridylmethyl)sulfinyl]benzimidazoles. 1. Their reaction with thiols under acidic conditions. Disulfide containing 2-pyridiniobenzimidazolides as mimics for the inhibited enzyme , 1987 .

[22]  P. Zeitoun,et al.  OMEPRAZOLE VERSUS RANITIDINE IN EROSIVE OESOPHAGITIS , 1987, The Lancet.

[23]  R. Pounder,et al.  Twenty‐four‐hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole , 1987, Alimentary pharmacology & therapeutics.

[24]  J. Jansen,et al.  DOUBLE-BLIND MULTICENTRE COMPARISON OF OMEPRAZOLE AND RANITIDINE IN THE TREATMENT OF REFLUX OESOPHAGITIS , 1987, The Lancet.

[25]  G. Sachs,et al.  Inhibition of (H+ + K+)-ATPase by omeprazole in isolated gastric vesicles requires proton transport. , 1987, Biochimica et biophysica acta.

[26]  D. Keeling,et al.  The specificity of omeprazole as an (H+ + K+)-ATPase inhibitor depends upon the means of its activation. , 1987, Biochemical pharmacology.

[27]  J. Lingrel,et al.  Molecular cloning of the rat stomach (H+ + K+)-ATPase. , 1986, The Journal of biological chemistry.

[28]  G. Sachs,et al.  Identification of a vanadate-sensitive potassium-dependent proton pump from rabbit colon. , 1986, The Journal of biological chemistry.

[29]  T. Lind,et al.  Inhibition of basal and betazole- and sham-feeding-induced acid secretion by omeprazole in man. , 1986, Scandinavian journal of gastroenterology.

[30]  J. Graef,et al.  Influence of the stimulation state of the parietal cells on the inhibitory effect of omeprazole on gastric acid secretion in dogs , 1986 .

[31]  G. Porro,et al.  A comparison of two different doses of omeprazole versus ranitidine in treatment of duodenal ulcers. , 1986, Journal of clinical gastroenterology.

[32]  P. Lindberg,et al.  The mechanism of action of the gastric acid secretion inhibitor omeprazole. , 1986, Journal of medicinal chemistry.

[33]  K. Hoffmann,et al.  Comparative metabolic disposition of oral doses of omeprazole in the dog, rat, and mouse. , 1986, Drug metabolism and disposition: the biological fate of chemicals.

[34]  O. Keyriläinen,et al.  Effects of omeprazole in duodenal ulcer patients. , 1986, Scandinavian journal of gastroenterology.

[35]  K. Hoffmann.  Identification of the main urinary metabolites of omeprazole after an oral dose to rats and dogs. , 1986, Drug metabolism and disposition: the biological fate of chemicals.

[36]  D. Hetzel,et al.  Long term management of hemorrhagic esophagitis with cimetidine and omeprazole. , 1986, Australian and New Zealand journal of medicine.

[37]  E. Fellenius,et al.  Inhibitory action of omeprazole on acid formation in gastric glands and on H+,K+-ATPase isolated from human gastric mucosa. , 1986, Scandinavian journal of gastroenterology.

[38]  R. Müller,et al.  Gastric (H+ + K+)‐ATPase: modulation of the inhibitory properties of the novel potent antisecretagogue Ro 18‐5364 by sulfhydryl reagents and nucleotides , 1986, FEBS letters.

[39]  F. Sundler,et al.  Plasma gastrin and gastric enterochromaffinlike cell activation and proliferation. Studies with omeprazole and ranitidine in intact and antrectomized rats. , 1986, Gastroenterology.

[40]  N. W. Spurling,et al.  Association of long lasting unsurmountable histamine H2 blockade and gastric carcinoid tumours in the rat. , 1985, Gut.

[41]  H. Larsson,et al.  The relationship between gastric acid secretion and gastric H+,K+-ATPase activity. , 1985, The Journal of biological chemistry.

[42]  P. Nicholson.  A multicenter international controlled comparison of two dosage regimes of misoprostol and cimetidine in the treatment of duodenal ulcer in out-patients , 1985, Digestive diseases and sciences.

[43]  A. Brändström,et al.  The mechanism for inhibition of gastric (H+ + K+)-ATPase by omeprazole. , 1985, Biochimica et biophysica acta.

[44]  W. Im,et al.  Omeprazole, a specific inhibitor of gastric (H+-K+)-ATPase, is a H+-activated oxidizing agent of sulfhydryl groups. , 1985, The Journal of biological chemistry.

[45]  A. Herling,et al.  2-((2-Pyridylmethyl)sulfinyl)benzimidazoles: acid sensitive suicide inhibitors of the proton transport system in the parietal cell. , 1985, Biochemical and biophysical research communications.

[46]  J. Rask-Madsen,et al.  Effect of omeprazole and cimetidine on duodenal ulcer. A double-blind comparative trial. , 1985, The New England journal of medicine.

[47]  R. Smallwood,et al.  Double blind comparative study of omeprazole 10 mg and 30 mg daily for healing duodenal ulcers. , 1985, British medical journal.

[48]  H. Larsson,et al.  Evidence for acid-induced transformation of omeprazole into an active inhibitor of (H+ + K+)-ATPase within the parietal cell. , 1984, Biochimica et biophysica acta.

[49]  G. Pals,et al.  Effect of oral omeprazole on serum gastrin and serum pepsinogen I levels. , 1984, Gastroenterology.

[50]  G. Sachs,et al.  Changes in cytosolic free Ca2+ in isolated parietal cells. Differential effects of secretagogues. , 1984, Biochimica et biophysica acta.

[51]  G. Bodemar,et al.  Effect of omeprazole, a substituted benzimidazole, on 24-h intragastric acidity in patients with peptic ulcer disease. , 1984, Scandinavian journal of gastroenterology.

[52]  E. C. Wood,et al.  Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity. , 1984, Gut.

[53]  J. G. Forte,et al.  Stimulation of oxyntic cell triggers K+ and Cl- conductances in apical H+-K+-ATPase membrane. , 1984, The American journal of physiology.

[54]  S. Sjöstrand,et al.  Inhibition of gastric acid secretion by omeprazole in the dog and rat. , 1983, Gastroenterology.

[55]  H. Adami,et al.  RAPID HEALING OF DUODENAL ULCERS WITH OMEPRAZOLE: DOUBLE-BLIND DOSE-COMPARATIVE TRIAL , 1983, The Lancet.

[56]  G. Sachs,et al.  Interaction of fluorescein isothiocyanate with the (H+ + K+)-ATPase. , 1983, Biochimica et biophysica acta.

[57]  U. Haglund,et al.  Effect of omeprazole--a gastric proton pump inhibitor--on pentagastrin stimulated acid secretion in man. , 1983, Gut.

[58]  G. Sachs,et al.  The interaction of H+ and K+ with the partial reactions of gastric (H+ + K+)-ATPase. , 1981, The Journal of biological chemistry.

[59]  G. Sachs,et al.  Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+) ATPase , 1981, Nature.

[60]  H. B. Stewart,et al.  The catalytic cycle of gastric (H+ + K+)-ATPase. , 1980, The Journal of biological chemistry.

[61]  G. Sachs,et al.  A nonelectrogenic H+ pump in plasma membranes of hog stomach. , 1976, The Journal of biological chemistry.

[62]  J. G. Forte,et al.  K + -stimulated ATPase in purified microsomes of bullfrog oxyntic cells. , 1973, Biochimica et biophysica acta.

[63]  J. Black,et al.  Definition and Antagonism of Histamine H2-receptors , 1972, Nature.

[64]  L. Sölvell.  The clinical safety of omeprazole. , 1990, Digestion.

[65]  P. Mulder,et al.  Nausea and Vomiting Induced by Cytostatic Agents , 1989 .

[66]  L. Tekenbergs-Hjelte,et al.  Chemical Reactions of Omeprazole and Omeprazole Analogues. III. Protolytic Behaviour of Compounds in the Omeprazole System. , 1989 .

[67]  P. Lindberg,et al.  Chemical Reactions of Omeprazole and Omeprazole Analogues. V. The Reaction of N-Alkylated Derivatives of Omeprazole Analogues with 2-Mercaptoethanol. , 1989 .

[68]  P. Lindberg,et al.  Chemical Reactions of Omeprazole and Omeprazole Analogues. VI. The Reactions of Omeprazole in the Absence of 2-Mercaptoethanol. , 1989 .

[69]  P. Lindberg,et al.  Chemical Reactions of Omeprazole and Omeprazole Analogues. I. A Survey of the Chemical Transformations of Omeprazole and its Analogues. , 1989 .

[70]  P. Lindberg,et al.  Chemical Reactions of Omeprazole and Omeprazole Analogues. IV. Reactions of Compounds of the Omeprazole System with 2-Mercaptoethanol. , 1989 .

[71]  W. Creutzfeldt,et al.  Long-term omeprazole treatment in man: effects on gastric endocrine cell populations. , 1988, Digestion.

[72]  A. Herling,et al.  A substituted thieno[3.4-d]imidazole versus substituted benzimidazoles as H+, K+-ATPase inhibitors. , 1988, Pharmacology.

[73]  W. Creutzfeldt,et al.  Therapy with omeprazole in patients with peptic ulcerations resistant to extended high-dose ranitidine treatment. , 1988, Digestion.

[74]  W. Hüttemann,et al.  20 versus 30 mg omeprazole once daily: effect on healing rates in 115 duodenal ulcer patients. , 1986, Digestion.

[75]  F. Sundler,et al.  Activation and hyperplasia of gastrin and enterochromaffin-like cells in the stomach. , 1986, Digestion.

[76]  G. Nilsson,et al.  Structure and Function of the Dog Gastric Mucosa During and After a 1–Year Treatment with Omeprazole. II. Effects on Gastric Acid Secretion and Blood Levels of Gastric Hormones , 1986 .

[77]  F. Sundler,et al.  Gastrin and the trophic control of gastric mucosa. , 1986, Scandinavian journal of gastroenterology. Supplement.

[78]  W. Creutzfeldt,et al.  Effect of short- and long-term feeding of omeprazole on rat gastric endocrine cells. , 1986, Digestion.

[79]  H. Larsson,et al.  Pharmacology and toxicology of omeprazole--with special reference to the effects on the gastric mucosa. , 1986, Scandinavian journal of gastroenterology. Supplement.

[80]  H. Hendrickx,et al.  Rate of Duodenal Ulcer Healing During Treatment with Omeprazole. A Double-Blind Comparison of a Daily Dose of 30 mg Versus 60 mg , 1986 .

[81]  N. Havu.  Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. , 1986, Digestion.

[82]  C. Regårdh.  Pharmacokinetics and metabolism of omeprazole in man. , 1986, Scandinavian journal of gastroenterology. Supplement.

[83]  P. Lindberg,et al.  Structure activity relationships of substituted benzimidazoles. , 1985, Scandinavian journal of gastroenterology. Supplement.

[84]  C. Regårdh,et al.  Localization of omeprazole and metabolites in the mouse. , 1985, Scandinavian journal of gastroenterology. Supplement.

[85]  L Ekman,et al.  Toxicological studies on omeprazole. , 1985, Scandinavian journal of gastroenterology. Supplement.

[86]  C. Regårdh,et al.  Pharmacokinetics and metabolism of omeprazole in animals and man--an overview. , 1985, Scandinavian journal of gastroenterology. Supplement.

[87]  J. Konturek,et al.  Effects of omeprazole, a substituted benzimidazole, on gastrointestinal secretions, serum gastrin, and gastric mucosal blood flow in dogs , 1984 .

[88]  M. Bins,et al.  The relation between basal gastric pH and serum gastrin. , 1982, Digestion.

[89]  G. Davidson,et al.  Letter: Rotavirus infections in obstetric hospitals. , 1975, Lancet.